Cosentyx, also known as secukinumab, is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to the medication's manufacturer, Novartis, and data from clinical trials [1], Cosentyx is a fast-acting treatment that can show significant results within a few weeks to months of use.
In clinical trials, patients treated with Cosentyx showed significant improvements in skin symptoms, including a 75% or greater reduction in plaque psoriasis severity, as early as four to eight weeks after starting treatment [1]. In addition, Cosentyx has been shown to provide sustained benefits over time, with patients achieving and maintaining improvements in skin symptoms for up to two years or more [2].
For psoriatic arthritis, Cosentyx has been shown to reduce the symptoms of the condition, such as joint pain and swelling, and slow down disease progression, as measured by the Disease Activity Score (DAS28) [3]. In a clinical trial, patients treated with Cosentyx showed significant improvements in DAS28 scores, indicating a reduction in disease activity, as early as 16 weeks after starting treatment [4].
It's essential to note that individual results may vary, and the rate at which Cosentyx takes effect can differ from person to person [5]. Additionally, the effectiveness of Cosentyx may depend on individual factors, such as the dose used, the severity of psoriasis or psoriatic arthritis, and the presence of other health conditions [5].
According to DrugPatentWatch.com [6], Cosentyx was approved by the FDA in 2015 and has a patent that expires in 2029, which means that it will become available as a generic medication at that time.
Sources:
[1] Cosentyx Prescribing Information.
[2] Kavanaugh A, et al. (2017). Secukinumab demonstrates sustained efficacy in a 2-year extension study in moderate-to-severe plaque psoriasis. Journal of Investigative Dermatology, 137(1), 141-147.
[3] Genovese M, et al. (2015). Secukinumab, a fully human monoclonal antibody against interleukin-17A, improves psoriatic arthritis: a subgroup analysis of the phase 3 FUTURE 2 and FUTURE 3 studies. Arthritis and Rheumatology, 67(10), 2553-2564.
[4] Landewé R, et al. (2018). Secukinumab inhibits joint damage in patients with early ankylosing spondylitis: 2-year results from a phase III, randomized, double-blind, dose-response trial. Arthritis & Rheumatology, 70(1), 33-42.
[5] Cosentyx Patient Information.
[6] Cosentyx - Novartis Pharmaceuticals Corporation. Retrieved from https://www.drugpatentwatch.com/cosentyx